Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9821)
All Articles published online
|
Publishing Process of This Article
|
Nov 7, 2017 (publication date) through Nov 3, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Kostas A, Siakavellas SI, Kosmidis C, Takou A, Nikou J, Maropoulos G, Vlachogiannakos J, Papatheodoridis GV, Papaconstantinou I, Bamias G. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. World J Gastroenterol 2017; 23(41): 7387-7396 [PMID: 29151692 DOI: 10.3748/wjg.v23.i41.7387] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v23/i41/7387.htm |
| Number | Citing Articles |
| 1 |
Akhilesh Swaminathan, Andrew S. Day, Miles P. Sparrow, Laurent Peyrin‐Biroulet, Corey A. Siegel, Richard B. Gearry. Review article: Measuring disease severity in inflammatory bowel disease – Beyond treat to target. Alimentary Pharmacology & Therapeutics 2024; 60(9): 1176 doi: 10.1111/apt.18231
|
| 2 |
Shin Young Park. Age-Related Fecal Calprotectin Concentrations in Healthy Adults. The Korean Journal of Clinical Laboratory Science 2020; 52(3): 181 doi: 10.15324/kjcls.2020.52.3.181
|
| 3 |
Vladislav Volarevic, Natasa Zdravkovic, Carl Randall Harrell, Nebojsa Arsenijevic, Crissy Fellabaum, Valentin Djonov, Miodrag L. Lukic, Bojana Simovic Markovic. Galectin-3 Regulates Indoleamine-2,3-dioxygenase-Dependent Cross-Talk between Colon-Infiltrating Dendritic Cells and T Regulatory Cells and May Represent a Valuable Biomarker for Monitoring the Progression of Ulcerative Colitis. Cells 2019; 8(7): 709 doi: 10.3390/cells8070709
|
| 4 |
Marianna Lucafò, Debora Curci, Matteo Bramuzzo, Patrizia Alvisi, Stefano Martelossi, Tania Silvestri, Veronica Guastalla, Flavio Labriola, Gabriele Stocco, Giuliana Decorti. Serum Adalimumab Levels After Induction Are Associated With Long-Term Remission in Children With Inflammatory Bowel Disease. Frontiers in Pediatrics 2021; 9 doi: 10.3389/fped.2021.646671
|
| 5 |
Amihai Rottenstreich, Tali Mishael, Sorina Grisaru Granovsky, Benjamin Koslowsky, Hagai Schweistein, Guila Abitbol, Eran Goldin, Ariella Bar-Gil Shitrit. Clinical utility of fecal calprotectin in monitoring disease activity and predicting relapse in pregnant patients with inflammatory bowel diseases. European Journal of Internal Medicine 2020; 77: 105 doi: 10.1016/j.ejim.2020.03.015
|
| 6 |
Paulina Nuñez F, Uma Mahadevan, Rodrigo Quera, Constanza Bay, Patricio Ibañez. Treat-to-target approach in the management of inflammatory Bowel disease. Gastroenterología y Hepatología 2021; 44(4): 312 doi: 10.1016/j.gastrohep.2020.06.032
|
| 7 |
|
| 8 |
Dan Turner, Amanda Ricciuto, Ayanna Lewis, Ferdinando D’Amico, Jasbir Dhaliwal, Anne M. Griffiths, Dominik Bettenworth, William J. Sandborn, Bruce E. Sands, Walter Reinisch, Jürgen Schölmerich, Willem Bemelman, Silvio Danese, Jean Yves Mary, David Rubin, Jean-Frederic Colombel, Laurent Peyrin-Biroulet, Iris Dotan, Maria T. Abreu, Axel Dignass. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology 2021; 160(5): 1570 doi: 10.1053/j.gastro.2020.12.031
|
| 9 |
Aleksandar Acovic, Bojana Simovic Markovic, Vladislav Volarevic, Tatjana Kanjevac, Danilo Vojvodic, Milica Velickovic, Natasa Zdravkovic, Vladimir Ristic. Lingua Plicata Associated with Increased Level of Proinflammatory Cytokines in Gingival Cervical Fluid: Possible New Sign in Ulcerative Colitis. Serbian Journal of Experimental and Clinical Research 2022; 0(0) doi: 10.2478/sjecr-2021-0006
|
| 10 |
Jin-Tong Shi, Nuo Chen, Jia Xu, Hemant Goyal, Zhi-Qi Wu, Jie-Xin Zhang, Hua-Guo Xu. Diagnostic Accuracy of Fecal Calprotectin for Predicting Relapse in Inflammatory Bowel Disease: A Meta-Analysis. Journal of Clinical Medicine 2023; 12(3): 1206 doi: 10.3390/jcm12031206
|
| 11 |
Olga Maria Nardone, Uday Nagesh Shivaji, Vittoria Ferruzza, Subrata Ghosh, Marietta Iacucci. Soluble Blood Markers of Mucosal Healing in Inflammatory Bowel Disease: The Future of Noninvasive Monitoring. Inflammatory Bowel Diseases 2020; 26(6): 961 doi: 10.1093/ibd/izz226
|
| 12 |
Mariusz A. Bromke, Katarzyna Neubauer, Radosław Kempiński, Małgorzata Krzystek-Korpacka. Faecal Calprotectin in Assessment of Mucosal Healing in Adults with Inflammatory Bowel Disease: A Meta-Analysis. Journal of Clinical Medicine 2021; 10(10): 2203 doi: 10.3390/jcm10102203
|
| 13 |
Wan-Ting Cao, Rong Huang, Shan Liu, Yi-Hong Fan, Mao-Sheng Xu, Yi Xu, Hui Ni. Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn’s disease under infliximab therapy. World Journal of Gastroenterology 2022; 28(23): 2582-2596 doi: 10.3748/wjg.v28.i23.2582
|
| 14 |
Ziheng Peng, Jun Yi, Xiaowei Liu. A Low-FODMAP Diet Provides Benefits for Functional Gastrointestinal Symptoms but Not for Improving Stool Consistency and Mucosal Inflammation in IBD: A Systematic Review and Meta-Analysis. Nutrients 2022; 14(10): 2072 doi: 10.3390/nu14102072
|
| 15 |
Gionata Fiorino, Silvio Danese, Laurent Peyrin‐Biroulet, Miquel Sans, Fabrizio Bonelli, Mariella Calleri, Claudia Zierold, Roberta Pollastro, Fabio Moretti, Alberto Malesci. LIAISON® Calprotectin for the prediction of relapse in quiescent ulcerative colitis: The EuReCa study. United European Gastroenterology Journal 2022; 10(8): 836 doi: 10.1002/ueg2.12268
|
| 16 |
Miljana Z. Jovandaric, Stefan Dugalic, Sandra Babic, Ivana R. Babovic, Srboljub Milicevic, Dejan Mihajlovic, Miljan Culjic, Tamara Zivanovic, Aleksandar Trklja, Bogdan Markovic, Vera Plesinac, Zorica Jestrovic, Biljana Medjo, Misela Raus, Miroslava Gojnic Dugalic. Programming Factors of Neonatal Intestinal Dysbiosis as a Cause of Disease. International Journal of Molecular Sciences 2023; 24(6): 5723 doi: 10.3390/ijms24065723
|
| 17 |
Aleksandar Acovic, Bojana Simovic Markovic, Marina Gazdic, Aleksandar Arsenijevic, Nemanja Jovicic, Nevena Gajovic, Marina Jovanovic, Natasa Zdravkovic, Tatjana Kanjevac, C. Randall Harrell, Crissy Fellabaum, Zana Dolicanin, Valentin Djonov, Nebojsa Arsenijevic, Miodrag L. Lukic, Vladislav Volarevic. Indoleamine 2,3-dioxygenase-dependent expansion of T-regulatory cells maintains mucosal healing in ulcerative colitis. Therapeutic Advances in Gastroenterology 2018; 11 doi: 10.1177/1756284818793558
|
| 18 |
Carlijn R. Lamers, Nicole M. de Roos, Coen C. W. G. Bongers, Dominique S. M. ten Haaf, Yvonne A. W. Hartman, Ben J. M. Witteman, Maria T. E. Hopman. Repeated prolonged moderate-intensity walking exercise does not appear to have harmful effects on inflammatory markers in patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology 2021; 56(1): 30 doi: 10.1080/00365521.2020.1845791
|
| 19 |
Andrew Leber, Raquel Hontecillas, Victoria Zoccoli-Rodriguez, Jean-Frederic Colombel, Jyoti Chauhan, Marion Ehrich, Nicholas Farinola, Josep Bassaganya-Riera. The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial. Inflammatory Bowel Diseases 2019; doi: 10.1093/ibd/izz094
|
| 20 |
Ruth M. Ayling, Klaartje Kok. . Advances in Clinical Chemistry 2018; 87: 161 doi: 10.1016/bs.acc.2018.07.005
|
| 21 |
Jun Kato, Takeichi Yoshida, Sakiko Hiraoka. Prediction of treatment outcome and relapse in inflammatory bowel disease. Expert Review of Clinical Immunology 2019; 15(6): 667 doi: 10.1080/1744666X.2019.1593140
|
| 22 |
Bailu Geng, Xueli Ding, Xiaoyu Li, Hua Liu, Wenjun Zhao, Haihong Gong, Zibin Tian, Jing Guo. Peripheral blood T-lymphocyte subsets are potential biomarkers of disease severity and clinical outcomes in patients with ulcerative colitis: a retrospective study. BMC Gastroenterology 2023; 23(1) doi: 10.1186/s12876-023-02769-5
|
| 23 |
Catherine R Rowan, Garret Cullen, Hugh E Mulcahy, Juliette Sheridan, Alan C Moss, Elizabeth J Ryan, Glen A Doherty. DUBLIN [Degree of Ulcerative colitis Burden of Luminal Inflammation] Score, a Simple Method to Quantify Inflammatory Burden in Ulcerative Colitis. Journal of Crohn's and Colitis 2019; 13(11): 1365 doi: 10.1093/ecco-jcc/jjz067
|
| 24 |
Y. B. Uspenskaya, S. J. Belogubova. DIAGNOSTIC POSSIBILITIES OF FECAL CALPROTECTIN APPLICATION IN PATIENTS WITH INFLAMMATORY DOWEL DISEASES DURING PREGNANCY (literature review and clinical observations). Koloproktologia 2018; (2): 95 doi: 10.33878/2073-7556-2018-0-2-95-101
|
| 25 |
Sabrina Cenni, Marianna Casertano, Marco Trani, Daniela Pacella, Massimo Martinelli, Annamaria Staiano, Erasmo Miele, Caterina Strisciuglio. The use of calgranulin-C (S100A12) and fecal zonulin as possible non-invasive markers in children with inflammatory bowel disease: a clinical study. European Journal of Pediatrics 2023; 182(3): 1299 doi: 10.1007/s00431-022-04771-7
|
| 26 |
Ghanya Al-Naqeb, Aliki Kalmpourtzidou, Rachele De Giuseppe, Hellas Cena. Beneficial Effects of Plant Oils Supplementation on Multiple Sclerosis: A Comprehensive Review of Clinical and Experimental Studies. Nutrients 2023; 15(22): 4827 doi: 10.3390/nu15224827
|
| 27 |
Akhilesh Swaminathan, Grace M Borichevsky, Teagan S Edwards, Esther Hirschfeld, Thomas C Mules, Chris M A Frampton, Andrew S Day, Mark B Hampton, Anthony J Kettle, Richard B Gearry. Faecal Myeloperoxidase as a Biomarker of Endoscopic Activity in Inflammatory Bowel Disease. Journal of Crohn's and Colitis 2022; 16(12): 1862 doi: 10.1093/ecco-jcc/jjac098
|
| 28 |
Reem Al-jabri, Panu Wetwittayakhlang, Peter L. Lakatos. Monitoring of Inflammatory Bowel Disease in Pregnancy: A Review of the Different Modalities. Journal of Clinical Medicine 2023; 12(23): 7343 doi: 10.3390/jcm12237343
|
| 29 |
Changchang Ge, Yi Lu, Hong Shen, Lei Zhu. Monitoring of intestinal inflammation and prediction of recurrence in ulcerative colitis. Scandinavian Journal of Gastroenterology 2022; 57(5): 513 doi: 10.1080/00365521.2021.2022193
|
| 30 |
Xue Guo, Chen Huang, Jing Xu, Haoming Xu, Le Liu, Hailan Zhao, Jiaqi Wang, Wenqi Huang, Wu Peng, Ye Chen, Yuqiang Nie, Yongjian Zhou, Youlian Zhou. Gut Microbiota Is a Potential Biomarker in Inflammatory Bowel Disease. Frontiers in Nutrition 2022; 8 doi: 10.3389/fnut.2021.818902
|
| 31 |
Ryan Ungaro, Jean-Frédéric Colombel, Trevor Lissoos, Laurent Peyrin-Biroulet. A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review. American Journal of Gastroenterology 2019; 114(6): 874 doi: 10.14309/ajg.0000000000000183
|
| 32 |
Yeoun Joo Lee, Jae Hong Park. Fecal Calprotectin Assay at an Early Stage of Treatment Can Be Used as a Surrogate Marker to Predict Clinical Remission and Mucosal Healing in Pediatric Crohn’s Disease. Pediatric Gastroenterology, Hepatology & Nutrition 2022; 25(5): 396 doi: 10.5223/pghn.2022.25.5.396
|
| 33 |
Paulina Nuñez F, Uma Mahadevan, Rodrigo Quera, Constanza Bay, Patricio Ibañez. Treat-to-target approach in the management of inflammatory Bowel disease. Gastroenterología y Hepatología (English Edition) 2021; 44(4): 312 doi: 10.1016/j.gastre.2020.06.023
|
| 34 |
Adam Makaro, Łukasz Dziki, Jakub Fichna, Marcin Włodarczyk. On the Way to Improve Diagnostic Marker Panel for Acute Appendicitis in Adults: the Role of Calprotectin. Indian Journal of Surgery 2022; 84(4): 634 doi: 10.1007/s12262-021-03063-y
|
| 35 |
Sylwia Fabiszewska, Edyta Derda, Edyta Szymanska, Marcin Osiecki, Jaroslaw Kierkus. Safety and Effectiveness of Vedolizumab for the Treatment of Pediatric Patients with Very Early Onset Inflammatory Bowel Diseases. Journal of Clinical Medicine 2021; 10(13): 2997 doi: 10.3390/jcm10132997
|
| 36 |
Dora Grgić, Karlo Golubić, Marko Brinar, Željko Krznarić. Predictive value of faecal calprotectin in ulcerative colitis – single centre experience. Annals of Medicine 2022; 54(1): 1570 doi: 10.1080/07853890.2022.2082518
|
| 37 |
Yoo Min Lee, Sujin Choi, Byung-Ho Choe, Hyo-Jeong Jang, Seung Kim, Hong Koh, Eun Sil Kim, Mi Jin Kim, Yon Ho Choe, Ben Kang. Association between Fecal Calprotectin and Mucosal Healing in Pediatric Patients with Crohn’s Disease Who Have Achieved Sustained Clinical Remission with Anti-Tumor Necrosis Factor Agents. Gut and Liver 2022; 16(1): 62 doi: 10.5009/gnl20300
|
| 38 |
Joel Tan Joel Tan, Teresa Neeman, Kavitha Subramaniam Kavitha Subramaniam. The utility of serum anti-tumour necrosis factor levels and biomarkers in predicting endoscopic activity in inflammatory bowel disease. Gastroenterology & Hepatology: Open Access 2022; 13(2): 53 doi: 10.15406/ghoa.2022.13.00494
|
| 39 |
Steve Halligan, Darren Boone, Lucinda Archer, Tariq Ahmad, Stuart Bloom, Manuel Rodriguez-Justo, Stuart A Taylor, Sue Mallett. Prognostic biomarkers to identify patients likely to develop severe Crohn’s disease: a systematic review. Health Technology Assessment 2021; 25(45): 1 doi: 10.3310/hta25450
|
| 40 |
Lorenzo Bertani, Maria Gloria Mumolo, Gherardo Tapete, Eleonora Albano, Giovanni Baiano Svizzero, Federico Zanzi, Linda Ceccarelli, Massimo Bellini, Santino Marchi, Francesco Costa. Fecal calprotectin: current and future perspectives for inflammatory bowel disease treatment. European Journal of Gastroenterology & Hepatology 2020; 32(9): 1091 doi: 10.1097/MEG.0000000000001731
|
| 41 |
Christopher Ma, Robert Battat, Claire E. Parker, Reena Khanna, Vipul Jairath, Brian Gordon Feagan. Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn’s disease?. Expert Review of Gastroenterology & Hepatology 2019; 13(4): 319 doi: 10.1080/17474124.2019.1563481
|
| 42 |
Lorenzo Bertani, Giorgia Bodini, Maria Gloria Mumolo, Nicola de Bortoli, Linda Ceccarelli, Leonardo Frazzoni, Gherardo Tapete, Eleonora Albano, Maria Corina Plaz Torres, Massimo Bellini, Edoardo Savarino, Vincenzo Savarino, Santino Marchi, Francesco Costa. Corticosteroid Treatment at Diagnosis: An Analysis of Relapses, Disease Extension, and Colectomy Rate in Ulcerative Colitis. Digestive Diseases and Sciences 2020; 65(8): 2397 doi: 10.1007/s10620-019-05959-y
|
| 43 |
Trifa Mahmood, Mohammed Mohammed, Dana Gharib, Taha Mohamad, Muhsin Mohammed, Araz Rahim. ROLE OF FECAL CALPROTECTIN IN DIFFERENTIATION OF INFLAMMATORY BOWEL DISEASES IN PATIENTS COMPLAINING OF ABDOMINAL SYMPTOMS AND REFERRED FOR COLONOSCOPY. JOURNAL OF SULAIMANI MEDICAL COLLEGE 2021; 11(1): 33 doi: 10.17656/jsmc.10285
|
| 44 |
Alice Jane Foster, Matthew Smyth, Alam Lakhani, Benjamin Jung, Rollin F Brant, Kevan Jacobson. Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients. World Journal of Gastroenterology 2019; 25(10): 1266-1277 doi: 10.3748/wjg.v25.i10.1266
|
| 45 |
Parul Tandon, Kristel Leung, Arif Yusuf, Vivian W. Huang. Noninvasive Methods For Assessing Inflammatory Bowel Disease Activity in Pregnancy. Journal of Clinical Gastroenterology 2019; 53(8): 574 doi: 10.1097/MCG.0000000000001244
|
| 46 |
Nikolas Plevris, Charlie W. Lees. Disease Monitoring in Inflammatory Bowel Disease: Evolving Principles and Possibilities. Gastroenterology 2022; 162(5): 1456 doi: 10.1053/j.gastro.2022.01.024
|
| 47 |
Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Eirini Theodoraki, Ioannis E. Koutroubakis. Recent Advances in the Optimization of Anti-TNF Treatment in Patients with Inflammatory Bowel Disease. Journal of Clinical Medicine 2023; 12(7): 2452 doi: 10.3390/jcm12072452
|
| 48 |
Tomer Ziv‐Baran, Séamus Hussey, Malgorzata Sladek, Jorge Amil Dias, Javier Martin de Carpi, Erasmo Miele, Gabor Veres, Paolo Lionetti, Sibylle Koletzko, Federica Nuti, Anders Paerregaard, Kaija‐Leena Kolho, Richard K. Russell, Ron Shaoul, Dror Weiner, Rotem Sigall Boneh, Johanna Escher, Lenne Finnby, Dan Turner, Arie Levine. Response to treatment is more important than disease severity at diagnosis for prediction of early relapse in new‐onset paediatric Crohn’s disease. Alimentary Pharmacology & Therapeutics 2018; 48(11-12): 1242 doi: 10.1111/apt.15016
|
| 49 |
Małgorzata Krzystek-Korpacka, Radosław Kempiński, Mariusz Bromke, Katarzyna Neubauer. Biochemical Biomarkers of Mucosal Healing for Inflammatory Bowel Disease in Adults. Diagnostics 2020; 10(6): 367 doi: 10.3390/diagnostics10060367
|
| 50 |
Henry Taylor, Jose Ivan Serrano‐Contreras, Julie A. K. McDonald, Jenny Epstein, JM Fell, Rocio C. Seoane, Jia V. Li, Julian R. Marchesi, Ailsa L. Hart. Multiomic features associated with mucosal healing and inflammation in paediatric Crohn’s disease. Alimentary Pharmacology & Therapeutics 2020; 52(9): 1491 doi: 10.1111/apt.16086
|
| 51 |
Monique Capron, Laurent Béghin, Céline Leclercq, Julien Labreuche, Arnaud Dendooven, Annie Standaert, Marie Delbeke, Adeline Porcherie, Maria Nachury, Arnaud Boruchowicz, Jean-Louis Dupas, Mathurin Fumery, Thierry Paupard, Sylviane Catteau, Dominique Deplanque, Jean-Frederic Colombel, Pierre Desreumaux. Safety of P28GST, a Protein Derived from a Schistosome Helminth Parasite, in Patients with Crohn’s Disease: A Pilot Study (ACROHNEM). Journal of Clinical Medicine 2019; 9(1): 41 doi: 10.3390/jcm9010041
|
| 52 |
Keeley M. Fairbrass, David J. Gracie, Alexander C. Ford. Relative Contribution of Disease Activity and Psychological Health to Prognosis of Inflammatory Bowel Disease During 6.5 Years of Longitudinal Follow-Up. Gastroenterology 2022; 163(1): 190 doi: 10.1053/j.gastro.2022.03.014
|
| 53 |
Yoo Min Lee, Eun Sil Kim, Sujin Choi, Hyo-Jeong Jang, Yu Bin Kim, So Yoon Choi, Byung-Ho Choe, Ben Kang. Fecal Calprotectin at Postinduction Is Capable of Predicting Persistent Remission and Endoscopic Healing after 1 Year of Treatment with Infliximab in Pediatric Patients with Crohn’s Disease. Gut and Liver 2024; 18(3): 498 doi: 10.5009/gnl230022
|
| 54 |
Amanda Ricciuto, Anne M. Griffiths. Clinical value of fecal calprotectin. Critical Reviews in Clinical Laboratory Sciences 2019; 56(5): 307 doi: 10.1080/10408363.2019.1619159
|
| 55 |
Nobuyuki Takahashi, Chinatsu Kitazawa, Yoshitaka Itani, Yuji Awaga, Aldric Hama, Ikuo Hayashi, Hiroyuki Takamatsu. Exploratory clinical characterization of experimentally-induced ulcerative colitis nonhuman primates. Heliyon 2020; 6(1): e03178 doi: 10.1016/j.heliyon.2020.e03178
|
| 56 |
Monica State, Lucian Negreanu, Theodor Voiosu, Andrei Voiosu, Paul Balanescu, Radu Bogdan Mateescu. Surrogate markers of mucosal healing in inflammatory bowel disease: A systematic review. World Journal of Gastroenterology 2021; 27(16): 1828-1840 doi: 10.3748/wjg.v27.i16.1828
|
| 57 |
Ying Cao, Yibei Dai, Lingyu Zhang, Danhua Wang, Wen Hu, Qiao Yu, Xuchu Wang, Pan Yu, Weiwei Liu, Ying Ping, Tao Sun, Yiwen Sang, Zhenping Liu, Yan Chen, Zhihua Tao. Combined Use of Fecal Biomarkers in Inflammatory Bowel Diseases: Oncostatin M and Calprotectin. Journal of Inflammation Research 2021; : 6409 doi: 10.2147/JIR.S342846
|